Boston Scientific has finalized its acquisition of Israeli energy-based medical solutions developer Lumenis Ltd. The sale price was $1.07 billion. This completes a deal that Boston Scientific first revealed in March.
Lumenis’ former owner will retain control of the Lumenis global aesthetics and ophthalmology businesses. With 2021 net sales anticipated to be approximately $200 million, the Lumenis surgical business includes premier laser systems, fibers and accessories used for urology and otolaryngology procedures. Foundational to its urology portfolio is the proprietary MOSES technology, which has demonstrated differentiated clinical outcomes and efficiency in the management of patients with kidney stones.
Lumenis works in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF).
Lumenis LTD was founded in 1966 and is headquartered in Yokneam, Israel. It has 1,500 employees including 450 in Israel. Boston Scientific has had a relationship with Lumenis for more than 20 years and currently sells the Lumenis urology laser portfolio in the U.S. and Japan through a distribution arrangement. Upon completion of the acquisition, Boston Scientific will sell these lasers and fibers – as well as the otolaryngology laser portfolio – to all geographies including high-growth regions like China.
“This has been a deal that I’ve been quite keen to do for a number of years,” said Meghan Scanlon, the president of Boston Scientific’s urology and pelvic health business. “After 20 years of a very successful partnership between Boston Scientific and Lumenis, the time was perfect to add this formally to our global portfolio.”
We’re excited to welcome @LumenisInc‘s surgical & otolaryngology businesses to Boston Scientific and add their portfolio of laser systems, fibers and accessories spearheaded by MOSES™ technology to our comprehensive stone management & BPH portfolios. https://t.co/yRI06k51M6 $BSX pic.twitter.com/5ebMH2Y4RJ
— Boston Scientific (@bostonsci) September 1, 2021
“The close of this acquisition allows us to integrate the Lumenis laser portfolio – including the differentiated MOSES™ technology – with our category leading kidney stone management and benign prostatic hyperplasia offerings while expanding our global footprint to accelerate growth throughout Europe and Asia,” she added. “ Additionally, we are welcoming significant talent to our Urology & Pelvic Health Team, and we are excited to establish our global surgical laser center of excellence in Yokneam, where we will continue our focus on advancing innovation to help surgeons improve patient care.”